Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01, RTT News reports. During the same period last year, the business posted ($0.37) EPS.
Nuvectis Pharma Stock Up 2.3 %
Shares of NVCT stock traded up $0.17 during trading hours on Wednesday, hitting $7.60. 48,815 shares of the company were exchanged, compared to its average volume of 102,267. The firm has a market cap of $141.74 million, a PE ratio of -5.86 and a beta of 0.41. Nuvectis Pharma has a 1 year low of $5.85 and a 1 year high of $12.10. The firm has a fifty day moving average of $6.79 and a 200 day moving average of $6.67.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a report on Tuesday, August 6th.
Nuvectis Pharma Company Profile
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Articles
- Five stocks we like better than Nuvectis Pharma
- Health Care Stocks Explained: Why You Might Want to Invest
- What a Trump Win Looks Like for the Market Now and Into 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What to Know About Investing in Penny Stocks
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
